Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma

Pavan Kumar Bhamidipati, Mark A. Fiala, Brenda J. Grossman, John F. DiPersio, Keith Stockerl-Goldstein, Feng Gao, Geoffrey L. Uy, Peter Westervelt, Mark A. Schroeder, Amanda F. Cashen, Camille N. Abboud, Ravi Vij

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences